GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver DiseaseBusiness Wire • 06/12/24
US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased RiskBusiness Wire • 06/07/24
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reachCNBC • 06/07/24
GSK: Still reasons to be cheerful rather than fearful after 'nightmare' MondayProactive Investors • 06/04/24
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuitsCNBC • 06/03/24